Carglumic Acid

Active ingredient: Carglumic Acid

In short: Carglumic acid tablets for oral suspension are indicated in adult and pediatric patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to NAGS deficiency. Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency.

Forms & strengthsTablets for oral suspension: 200 mg of carglumic acid, white to off-white, elongated, functionally scored with 3 lines (for splitting into 4 equal portions) and coded "120" on one side and ''N" on other side.
LabelEton Pharmaceuticals, Inc.
Label updatedMar 05, 2026

What is Carglumic Acid used for?

Carglumic acid tablets for oral suspension are indicated in adult and pediatric patients as:

Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to NAGS deficiency.

Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency.

Carglumic Acid dosage

Disperse carglumic acid tablets for oral suspension in water. Do not swallow whole or crush .

Carglumic acid tablets for oral suspension may be administered by mouth or via a nasogastric or gastrostomy tube .

Treatment Initiation

Initiate carglumic acid tablets for oral suspension treatment as soon as the diagnosis of NAGS deficiency is suspected, which may be as soon as at birth, and supervised by a healthcare provider experienced in the treatment of metabolic disorders.

Dosage for Acute Hyperammonemia due to NAGS Deficiency

The recommended dosage of carglumic acid tablets for oral suspension in adult and pediatric patients for acute hyperammonemia due to NAGS deficiency is (based on actual body weight) 100 mg/kg to 250 mg/kg orally daily.

Divide the daily dosage into 2 to 4 doses and round to the nearest 100 mg (i.e., half of a carglumic acid tablet for oral suspension).

During acute hyperammonemic episodes, administer carglumic acid tablets for oral suspension with other ammonia lowering therapies, such as alternate pathway medications, hemodialysis, and protein restriction.

Dosage for Chronic Hyperammonemia due to NAGS Deficiency

The recommended dosage of carglumic acid tablets for oral suspension in adult and pediatric patients for chronic hyperammonemia due to NAGS deficiency is (based on actual body weight) 10 mg/kg to 100 mg/kg orally daily.

Divide the daily dosage into 2 to 4 doses and round to the nearest 100 mg (i.e., half of a Carglumic acid tablet for oral suspension).

During maintenance therapy, the concomitant use of other ammonia lowering therapies and protein restriction may be needed based on plasma ammonia levels.

Therapeutic Monitoring

Closely monitor plasma ammonia levels. Titrate the Carglumic acid tablets for oral suspension dosage to maintain the plasma ammonia level within the normal range for the patient’s age, taking into consideration their clinical condition (e.g., nutritional requirements, protein intake, growth parameters, etc.).

Adjust the recommended dosage in patients with moderate or severe renal impairment .

No dosage adjustment is warranted in patients with mild renal impairment (eGFR 60-89 mL/min/1.73 m2). The recommended dosage of Carglumic acid tablets for oral suspension in patients with moderate or severe renal impairment is shown below. …

How to take Carglumic Acid — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Instructions for Use).

Advise the patient or caregiver on the following:

Preparation and Administration

Disperse Carglumic acid tablets for oral suspension in water. Do not swallow whole or crushed.

Take Carglumic acid tablets for oral suspension immediately before meals or feedings.

Carglumic acid tablets for oral suspension dispersed in water can be administered orally or via a nasogastric tube or gastrostomy tube as described in the Instructions for Use.

Storage

Store UNOPENED bottle at 20° to 25°C (68° to 77°F) .

After first opening of the bottle: do not refrigerate, store at room temperature between 20° to 25°C (68° to 77°F). Keep the bottle tightly closed in order to protect from moisture. Write the date of opening on the bottle.

Discard bottle after 90 days from first opening. Do not use carglumic acid tablets for oral suspension after the expiration date stated on the bottle.

All Trademarks are the property of their respective owners.

Manufactured by:

Novitium Pharma LLC

70 Lake Drive, East WindsorNew Jersey 08520

Distributed by:

Eton Pharmaceuticals, Inc.

Deer Park, IL 60010USA

Issued: 01/2024LB4191-04

Warnings & precautions

Do not take this medicine if: None

Carglumic Acid side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Acute and Chronic Hyperammonemia due to NAGS Deficiency

In a retrospective case series of 23 NAGS deficiency patients treated with Carglumic acid tablets for oral suspension, 17 of the 23 patients reported an adverse reaction. The most common adverse reactions (occurring in ≥ 13% of patients) were vomiting, abdominal pain, pyrexia, tonsillitis, anemia, diarrhea, ear infection, infections, nasopharyngitis, hemoglobin decreased, and headache.

Table 1 summarizes adverse reactions occurring in 2 or more patients treated with Carglumic acid tablets for oral suspension. …

About this medicine

Carglumic acid tablets for oral suspension contain 200 mg of carglumic acid. Carglumic acid, the active substance, is a carbamoyl phosphate synthetase 1 (CPS 1) activator and is soluble in boiling water, slightly soluble in cold water, and practically insoluble in organic solvents.

The chemical name of carglumic acid is N-carbamoyl-L-glutamic acid or (2S)-2-(carbamoylamino) pentanedioic acid. The empirical formula is C6H10N2O5 and the molecular weight is 190.16.

The structural formula is:

The inactive ingredients of Carglumic acid tablets for oral suspension are croscarmellose sodium, microcrystalline cellulose, colloidal silicon dioxide, sodium lauryl sulfate, sodium stearyl fumarate, magnesium stearate, mannitol and povidone.

How it works: Carglumic acid is a synthetic structural analogue of N-acetylglutamate (NAG) which is produced from glutamate and acetyl-CoA in a reaction catalyzed by N-acetylglutamate synthase (NAGS), a mitochondrial liver enzyme. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 591f95ca-3d99-4fb6-a402-e5a383a746d0. Read the full official label on DailyMed.